Morgan Stanley, Cowen, RBC were the bookrunners; Oppenheimer assisted
By Devika Patel
Knoxville, Tenn., Aug. 19 – Ocular Therapeutix, Inc. said the underwriters for its initial public offering of stock opted to exercise the deal’s $9.75 million greenshoe in full, lifting total proceeds to $74.75 million. The deal was announced June 20 and priced for $65 million with the greenshoe on July 25.
The company sold 5.75 million common shares at $13.00 apiece. Of the shares, 750,000 were part of the fully exercised greenshoe.
Morgan Stanley & Co. LLC, Cowen and Co. and RBC Capital Markets were the joint bookrunning managers.
Proceeds will be used for clinical trials, research and development, sales and marketing, expanding manufacturing capacity, working capital and other general corporate purposes.
The biopharmaceutical company is based in Bedford, Mass. The company intends to list its common stock on the Nasdaq under the symbol “OCUL.”
| Issuer: | Ocular Therapeutix, Inc.
|
| Issue: | Common stock
|
| Amount: | $74.75 million, including $9.75 million greenshoe
|
| Shares: | 5.75 million
|
| Price: | $13.00
|
| Warrants: | No
|
| Bookrunners: | Morgan Stanley & Co. LLC, Cowen and Co., RBC Capital Markets
|
| Co-manager: | Oppenheimer & Co.
|
| Announcement date: | June 20
|
| Pricing date: | July 25
|
| Settlement date: | Aug. 19
|
| Stock exchange: | Nasdaq: OCUL
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
